Altered Gene Expression Pattern in Peripheral Blood Mononuclear Cells in Patients with Acute Myocardial Infarction

Kiliszek, Marek; Burzyńska, Beata; Michalak, Marcin; Góra, Monika; Winkler, Aleksandra; Maciejak, Agata; Leszczynska, Agata; Gajda, Ewa; Kochanowski, Janusz; Opolski, Grzegorz

doi:10.1371/journal.pone.0050054

Cited by 74 publications

(62 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using gene expression profiles, we can obtain adequate information about altered gene expression correlating with disease. Kiliszek et al (2012) utilized a microarray approach to demonstrate that, during ST-segment elevation myocardial infarction (STEMI), many genes have altered expression, including those involved in various pathways related to platelet function, lipid/glucose metabolism and atherosclerotic plaque stability. Based on the system level of gene expression profiling, gene co-expression network analyses could be an alternative method for analyzing expression profiling data (Stuart et al, 2003), in order to gain an insight into molecular regulatory mechanisms of heart diseases caused by myocardial infarction.…”

Section: Introductionmentioning

confidence: 99%

Network Analysis-Based Approach for Exploring the Potential Diagnostic Biomarkers of Acute Myocardial Infarction

Chen

Zhang

et al. 2016

Front. Physiol.

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) is a severe cardiovascular disease that is a serious threat to human life. However, the specific diagnostic biomarkers have not been fully clarified and candidate regulatory targets for AMI have not been identified. In order to explore the potential diagnostic biomarkers and possible regulatory targets of AMI, we used a network analysis-based approach to analyze microarray expression profiling of peripheral blood in patients with AMI. The significant differentially-expressed genes (DEGs) were screened by Limma and constructed a gene function regulatory network (GO-Tree) to obtain the inherent affiliation of significant function terms. The pathway action network was constructed, and the signal transfer relationship between pathway terms was mined in order to investigate the impact of core pathway terms in AMI. Subsequently, constructed the transcription regulatory network of DEGs. Weighted gene co-expression network analysis (WGCNA) was employed to identify significantly altered gene modules and hub genes in two groups. Subsequently, the transcription regulation network of DEGs was constructed. We found that specific gene modules may provide a better insight into the potential diagnostic biomarkers of AMI. Our findings revealed and verified that NCF4, AQP9, NFIL3, DYSF, GZMA, TBX21, PRF1 and PTGDR genes by RT-qPCR. TBX21 and PRF1 may be potential candidates for diagnostic biomarker and possible regulatory targets in AMI.

show abstract

Section: Introductionmentioning

confidence: 99%

Network Analysis-Based Approach for Exploring the Potential Diagnostic Biomarkers of Acute Myocardial Infarction

Chen

Zhang

et al. 2016

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…34,35 Similar studies using peripheral blood mononuclear cells have also identified genes related to adaptive immunity as being associated with MI. 36 Of note, most studies of the expressed genome in MI cannot determine whether changes in gene expression are the cause or the result of MI. However, platelets lack nuclei, and their mRNA levels are established at the time of megakaryopoiesis.…”

Section: Musunuru Et Al Expressed Genome In Cardiovascular Diseases Amentioning

confidence: 99%

The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association

Musunuru¹,

Ingelsson²,

Fornage³

et al. 2017

Circ Cardiovasc Genet

View full text Add to dashboard Cite

Abstract-There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications, RNA transcripts, proteins, and metabolites, which together can be considered the "expressed genome." The emergence of high-throughput technologies, including epigenomics, transcriptomics, proteomics, and metabolomics, is now making it possible to address the contributions of the expressed genome to cardiovascular disorders. This statement describes how the expressed genome can currently and, in the future, potentially be used to diagnose diseases and to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrhythmias. (Circ Cardiovasc Genet. 2017;10:e000037. DOI: 10.1161/HCG.0000000000000037.)Key Words: AHA Scientific Statements ◼ cardiovascular diseases ◼ DNA ◼ epigenomics ◼ genome ◼ metabolomics ◼ proteomics ◼ strokeThe American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on March 13, 2017, and the American Heart Association Executive Committee on April 17, 2017. A copy of the document is available at http://professional.heart.org/statements by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@ wolterskluwer.com.The American Heart Association requests that this document be cited as follows: Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://professional.heart.org/statements. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/CopyrightPermission-Guidelines_UCM_300404_Article.jsp. A link to the "Copyright Permissions Request Form" appears on the right side of the page. I n no small part as a result of the completion of the Human Genome Project, considerable effort has been invested over the past few decades in understanding the contribution of genetics to the risk of cardiovascular diseases and stroke. Genomewide association studies, candidate gene sequencing studies, a...

show abstract

“…The identified target mRNAs were clustered in several pathways, including inflammatory pathways involving PPAR, IL-6, IL-10, natural killer cell, and glucocorticoid receptor signaling; cholesterol metabolism involving liver X and retinoic acid receptor activation; and the extrinsic pathway of the coagulation system. Interestingly, mRNA expression changed across the different time points, suggesting that there exists an mRNA signature for acute STEMI [53] that could be used to facilitate diagnosis settings where immediate access to trained personnel is limited. These discoveries reflect the intimate relationships between cholesterol deposition, intimal proliferation and inflammation, and acute thrombosis involved in the natural history of CAD.…”

Section: Detecting MImentioning

confidence: 99%

Gene Expression Signatures and the Spectrum of Coronary Artery Disease

Friede

Ginsburg

Voora

2015

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

Over the past 10-15 years, developments in gene expression profiling have opened new arenas for the discovery of important factors in the pathogenesis of numerous disease processes, including coronary artery disease. Messenger RNA and microRNA are differentially expressed in patients with coronary plaques, acute plaque rupture, and response to well-established treatments for acute coronary syndromes. In this review, we will explore recent developments in messenger RNA and microRNA technology at each stage of a patient's progression through the natural history of cardiovascular disease, including evaluation of risk factors, prediction and detection of coronary artery disease and acute coronary syndromes, and finally, response to treatments for coronary artery disease and its sequelae including congestive heart failure.

show abstract

Altered Gene Expression Pattern in Peripheral Blood Mononuclear Cells in Patients with Acute Myocardial Infarction

Cited by 74 publications

References 38 publications

Network Analysis-Based Approach for Exploring the Potential Diagnostic Biomarkers of Acute Myocardial Infarction

Network Analysis-Based Approach for Exploring the Potential Diagnostic Biomarkers of Acute Myocardial Infarction

The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association

Gene Expression Signatures and the Spectrum of Coronary Artery Disease

Contact Info

Product

Resources

About